 TOKYOBUSINESS WIREMeiji Seika Pharma Co., Ltd. Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi and the Foundation for Biomedical Research and Innovation at Kobe Headquarters: Kobe, Japan, President: Tasuku Honjo, hereinafter FBRI announce the discovery of a novel anti-PD-1 agonist monoclonal antibody, which can induce immunosuppressive effect, through their collaborative research on Treatment of ...... 